-
Preferences for Parkinson's Disease Treatments: A Scoping Literature Review
Mar 10, 2025, 14:00 PM -
Mapping Health-Related Quality of Life (HRQoL) Measures to Preference Based Measures in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): A systematic literature review
Mar 10, 2025, 14:00 PM -
Real-World Adherence, Healthcare Resource Utilization, And Costs Among Patients With Schizophrenia Utilizing Once-Monthly, Once-Every-Three-Months, And Once-Every-Six-Months Paliperidone Palmitate in the United States
Mar 10, 2025, 14:00 PM -
Nirsevimab for RSV Prevention in Hong Kong Infants: A Cost-Effectiveness Analysis
Mar 10, 2025, 14:00 PM -
Real-World Effectiveness of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in Poland in Comparison With Efficacy Reported in Clinical Trials
Mar 10, 2025, 14:00 PM -
The Impact of Meeting Orphan Criteria on Reimbursement Decisions and ICERs in Scotland
Mar 10, 2025, 14:00 PM -
Clinical Value of Testing for c-Met Protein Overexpression in Patients With Non-Small Cell Lung Cancer
Mar 10, 2025, 14:00 PM -
Measuring Patient- and Carer-Reported Outcomes Following Genome Sequencing for Rare Disease Diagnosis: A Psychometric Assessment of Outcome Measurement Instruments
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness Analysis of Lenvatinib vs Key Comparators in First-Line Unresectable Hepatocellular Carcinoma in Canada
Mar 10, 2025, 14:00 PM -
Characterizing Improvements in Physical Functioning with PROMIS-PF and In-Trial Exit Interviews: A Mixed-Methods Analysis to Understand the Meaningful Changes Experienced by TGCT Patients on Vimseltinib in the MOTION Trial
Mar 10, 2025, 14:00 PM -
Risk of Cutaneous Adverse Drug Reactions with GLP-1 Receptor Agonists: Insights from FAERS and Systematic Review
Mar 10, 2025, 14:00 PM -
Cost-Utility analysis of Dinutuximab Beta in Treating High-Risk Neuroblastoma: A Partitioned Survival Model Using R programming Language
Mar 10, 2025, 14:00 PM -
Cost-effectiveness of Esketamine versus Real-world Treatments for Patients with Treatment-resistant Depression: A Multi-armed Modelling Study
Mar 10, 2025, 14:00 PM -
An Economic Model Exploring the Impact of Formulary Restrictions on the Incidence and Cost of Clinical Events in Patients with Non-Valvular Atrial Fibrillation Receiving Direct Oral Anticoagulants in the United States
Mar 10, 2025, 14:00 PM -
Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality of Life (HRQoL) Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Mar 10, 2025, 14:00 PM -
Conceptual Framework for a De Novo Cost-effectiveness Model in Glycogen Storage Disease Type Ia (GSDIa)
Mar 10, 2025, 14:00 PM -
Do Framing and Attribute Number Influence Choice Consistency in a Preference-Based Value Assessment of Equity and Efficiency?
Mar 10, 2025, 14:00 PM -
Cost Comparison of Osimertinib Plus Chemotherapy Versus Amivantamab Plus Lazertinib for the First-Line Treatment of Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC
Mar 10, 2025, 14:00 PM -
Trends In Oral JAK Inhibitor And Other Drug Use For Myelofibrosis: A Retrospective Real-World Study
Mar 10, 2025, 14:00 PM -
Interventions To Overcome the Challenges for Identifying Substandard, Spurious, Falsely Labeled, Falsified and Counterfeit Drugs (SSFFC).A Systematic Review.
Mar 10, 2025, 14:00 PM
